ClinicalTrials.gg
CompletedNCT00184678Updated Jan 13, 2017

Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency

A Phase 3 interventional study of somatropin in Growth Hormone Disorder and Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Completed at 30 sites in 12 countries. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
14th of 60
161 · median 66
Started
2002
with 1 other
Phase 3
23 of 60
2 open now
Registered
11th of 60
by date
Lead sponsor
8 of 60
Novo Nordisk A/S

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 14th largest by enrollment, is one of 2 that started in 2002, is one of 23 in phase 3, and was the 11th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This trial is conducted in Europe. Growth Hormone in young adults with growth hormone deficiency in childhood. This trial compares a treated group of patients with an untreated group of patients.

03

Conditions studied

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child-hood onset growth hormone deficiency
  • Subjects received growth hormone replacement therapy during pre-puberty and puberty

Exclusion criteria

Exclusion Criteria:

  • GH treatment during the month preceding randomisation
  • Treatment within the previous 6 months with medication that may affect bone mineral density
  • Diseases which may affect bone metabolism
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
161 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in bone mineralisation

    Time frame: After 2 years treatment

Secondary outcomes

  1. Other markers of bone mineral content.

07

Study locations

30 sites
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3052, Australia
  • Novo Nordisk Investigational Site
    Auckland, 1, Australia
  • Novo Nordisk Investigational Site
    Hamilton, 2303, Australia
  • Novo Nordisk Investigational Site
    Subiaco, 6008, Australia
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Bruxelles, 1200, Belgium
  • Novo Nordisk Investigational Site
    Le Kremlin-bicetre, 94275, France
  • Novo Nordisk Investigational Site
    MARSEILLE Cédex 05, 13385, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31059, France
  • Novo Nordisk Investigational Site
    Essen, 45122, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Heidelberg, 69115, Germany
  • Novo Nordisk Investigational Site
    Krefeld, 47805, Germany
  • Novo Nordisk Investigational Site
    Leipzig, 04317, Germany
  • Novo Nordisk Investigational Site
    Magdeburg, 39112, Germany
  • Novo Nordisk Investigational Site
    Budapest, 1088, Hungary
  • Novo Nordisk Investigational Site
    Budapest, 1135, Hungary
  • Novo Nordisk Investigational Site
    Szeged, 6720, Hungary
  • Novo Nordisk Investigational Site
    Oslo, 0027, Norway
  • Novo Nordisk Investigational Site
    Cracow, 30-663, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-952, Poland
  • Novo Nordisk Investigational Site
    Szczecin, 71-455, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 04-736, Poland
  • Novo Nordisk Investigational Site
    Wroclaw, 50-376, Poland
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Göteborg, 413 45, Sweden
  • Novo Nordisk Investigational Site
    Bern, 3010, Switzerland
  • Novo Nordisk Investigational Site
    Lausanne, 1011, Switzerland
  • Novo Nordisk Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • Novo Nordisk Investigational Site
    London, W1N 8AA, United Kingdom
08

References and documents

Publications

  • Zacharin M, Szarras-Czapnik M, Racz K, Keller A, Tauber M, Conway G. Growth hormone (GH) treatment improves bone mineral density during transition of GH-deficient patients from adolescence to adulthood. European Society for Paediatric Endocrinology (ESPE) 2007; Country: Finland City: Helsinki
  • Zacharin M, Keller A, Chanson P, Conway G on behalf of the 1369 GHD to GHDA. Efficacy of two years' growth hormone (GH) treatment on bone mineral density in young adults with childhood-onset GH deficiency. The Endocrine Society Annual Meeting (ENDO) 2007; Country: Canada City: Toronto
  • Conway G, Scarras-Czapnik M, Racz K, Keller A, Chanson P, Kappelgaard A M, Zacharin M, Hyldstrup L. Direct X-ray radiogrammetry versus dual-energy X-ray absorptiometry: assessment of bone density in young adult with childhood-onset growth hormone deficiency treated with growth hormone. The Endocrine Society Annual Meeting (ENDO) 2008; Country: USA City: San Francisco
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
Start
Feb 2002
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00184678
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Feb 2002
Primary completion
Jul 2006
Completion
Jul 2006
Last update
Jan 13, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion